Vemlidy costs roughly $1,558 for a 30-day supply at wholesale, making it one of the more expensive daily medications for chronic hepatitis B. The high price comes down to a combination of patent protection extending through 2032, a deliberate pharmaceutical strategy to shift patients away from cheaper alternatives, and limited generic competition in practice despite one FDA-approved generic existing on paper.
What Vemlidy Actually Costs
The current wholesale acquisition cost for Vemlidy is about $51.93 per tablet, which works out to approximately $1,558 per month or nearly $19,000 per year. That’s the price pharmacies pay to stock the drug, not what you’d pay at the counter. Your actual out-of-pocket cost depends on your insurance, but without coverage or a coupon, you’d be looking at something close to that figure.
For context, the older version of the same core drug, tenofovir disoproxil fumarate (sold as Viread), is available as a generic for roughly $4.89 per day in markets like Canada. Vemlidy’s daily cost runs about $19.55, roughly four times higher. A Canadian health agency calculated that Vemlidy would need a 75% price reduction just to be considered cost-neutral compared to generic tenofovir. That gap of nearly $5,400 per year is the premium you’re paying.
The Patent Strategy Behind the Price
Vemlidy’s active ingredient, tenofovir alafenamide (TAF), is a reformulated version of the older tenofovir disoproxil fumarate (TDF). Both deliver the same antiviral compound to the body, but TAF does so at a lower dose, which may reduce long-term side effects on kidneys and bones. That “may” is important: the reformulation gave Gilead Sciences a basis for new patents, even though the underlying drug concept isn’t new.
Patent protection for the older TDF expired in 2018, and generic versions became available in 2020. But Gilead holds patents on TAF that don’t expire until August 2032. This is a well-documented pharmaceutical tactic called “evergreening,” where a company develops a modified version of its own drug before the original loses patent protection, then moves patients onto the new, patent-protected version.
Gilead was explicit about this approach. The company actively converted patients from TDF-based products to TAF-based ones before generic TDF became available. Because clinicians had genuine concerns about TDF’s long-term effects on kidneys and bones, insurers found it difficult to push patients back to the cheaper generic once they’d already switched. The result: even when a much cheaper option existed, spending on these treatments went up, not down.
Why Generic Competition Hasn’t Lowered the Price
Here’s something that surprises most people: the FDA actually approved a generic version of Vemlidy in March 2023, manufactured by Lupin Limited. So why hasn’t the price dropped?
That approval was tentative, meaning the FDA confirmed the generic meets safety and effectiveness standards but the manufacturer can’t actually sell it yet because of Gilead’s active patents. The key patent doesn’t expire until August 2032, and two separate patents cover that date. Until those patents expire or are successfully challenged, generic manufacturers are locked out of the U.S. market. The FDA approval essentially puts the generic in a holding pattern for years.
Vemlidy has additional Orange Book patents with earlier dates (one expired in 2022, another in April 2025), but the 2032 patents are the ones that matter. They form the real barrier to price competition.
How Gilead Manages Pricing Across Products
Gilead’s pricing strategy varies depending on the product and market. For its TAF-based PrEP drug Descovy, the company offered larger commercial discounts at launch, which made it easier to move patients over from the older Truvada before generics arrived. Within nine months of Descovy’s approval for PrEP, 30% of prescriptions had already shifted over, according to analysis by the CDC.
For treatment products (as opposed to prevention), Gilead took a different approach: lower discounts, which translated to higher net prices for insurers. The logic was straightforward. When a drug is used for long-term treatment of a chronic condition, doctors and patients are more reluctant to switch back to an older formulation with known side-effect concerns. Insurers have less leverage to demand the cheaper option, and the manufacturer can hold firmer on price. This dynamic applies directly to Vemlidy, which is a long-term treatment for chronic hepatitis B.
What U.S. Patients Pay Compared to Other Countries
Vemlidy’s pricing in the U.S. is high even compared to other wealthy nations. In Canada, the submitted manufacturer price for TAF ranged from about $18.49 to $19.55 per day depending on the province, based on 2018 data. While that’s also expensive, Canada’s public drug plans negotiate collectively and can reject drugs that don’t demonstrate enough value over cheaper alternatives. The Canadian drug review agency specifically flagged Vemlidy’s price premium as unjustified relative to generic TDF.
In countries like India, where Gilead has licensed generic production for some of its antiviral drugs, versions of tenofovir alafenamide are available at a fraction of the U.S. cost. This global pricing gap is common for brand-name drugs, but it’s especially stark for medications treating chronic conditions that require years or decades of daily use.
Options for Reducing Your Cost
Gilead runs a patient assistance program called Advancing Access that offers two main pathways. A co-pay savings program helps commercially insured patients cover out-of-pocket costs. A separate patient assistance program provides the medication at no cost to eligible uninsured or underinsured patients. You need to be a U.S. resident to qualify, and if you’re enrolled in Medicaid or the AIDS Drug Assistance Program, you may not be eligible for the free medication program.
Beyond Gilead’s own programs, some patients work with specialty pharmacies or nonprofit organizations that help navigate manufacturer coupons and state-level assistance. If you’re paying out of pocket, it’s worth checking whether your prescriber can document medical necessity to unlock better insurance coverage, since hepatitis B treatment is generally considered essential by most formulary committees.
The fundamental pricing picture is unlikely to change until 2032, when Gilead’s key patents expire and generic manufacturers can enter the market. At that point, if the pattern of other antiviral generics holds, prices could drop significantly within the first year or two of competition.